NVSNovartis PharmaceuticalsRunning, no new patients
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Early Breast Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 1,466 (final count)
- Started
- Feb 28, 2024
- Main results expected
- Sep 7, 2029
- Fully finished
- Sep 20, 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Invasive Breast Cancer Free Survival (iBCFS) rate at 3 years
Measured over: At 3 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05827081 · record last updated 2026-11-03 · checked 2026-11-09 15:47 UTC